logo-loader
viewGenprex, Inc.

Genprex reaches deal with Aldevron for more plasmid DNA for expanding clinical program

Genprex Inc (NASDAQ:GNPX) CEO Rodney Varner updates Proactive's Christine Corrado at the MicroCap Conference in New York.

The clinical-stage gene therapy company has reached a deal with Aldevron, a contract manufacturer, to receive a supply of TUSC2 (Tumor Suppressor Candidate 2) plasmid DNA for use in its clinical development program, which is evaluating its therapy Oncoprex for the treatment of non-small cell lung cancer.

Quick facts: Genprex, Inc.

Price: 0.5 USD

NASDAQ:GNPX
Market: NASDAQ
Market Cap: $7.66 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Genprex, Inc. named herein, including the promotion by the Company of Genprex, Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Genprex's active drug ingredient validated by independent...

Genprex (NASDAQ:GNPX) CEO Rodney Varner tells Proactive that the active ingredient in the biotech firm's immunogene therapy Oncoprex has been shown to prevent tumor growth in triple-negative breast cancer patients by an independent researcher. Varner notes the study was published in the...

on 09/20/2019

2 min read